

ASX Announcement
9 April 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan to Showcase Imaging Tech at Site Tour

Health analysts to gain first-hand access to Optiscan’s breakthrough imaging technology, commercialisation strategy, and market opportunities.

Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or the ‘Company’) will host a site tour for health analysts at its headquarters in Mulgrave, Victoria on Thursday, April 10, 2025, providing attendees with the opportunity to engage with the Company’s leadership team and gain insight into its cutting-edge miniaturised confocal laser endomicroscopy technology platform devices.

During the visit, attendees will receive a detailed overview of Optiscan’s strategic direction, commercialisation progress, and key milestones across its three core markets:

- Medical – advancing real-time digital pathology and precision surgery
- Veterinary – expanding imaging capabilities into animal healthcare
- Life Sciences – enabling high-resolution live-cell imaging in preclinical research

The visit will include live demonstrations of Optiscan’s expanding product range, including:

- InVue™ – a next-generation system for surgical applications
- InForm™ – digital pathology technology
- InVivage® – an intra-oral endomicroscope
- ViewnVivo® – a high-resolution imaging system for real-time life sciences research

In addition, Optiscan will provide an overview of its Software-as-a-Medical-Device (SaMD) initiatives, particularly in telepathology and AI-driven diagnostics, which form a key part of the Company’s future growth strategy.

The event will include a presentation from Optiscan’s Chief Executive Officer, Dr Camile Farah, followed by a Q&A session and tour of the facilities.

For further details and RSVP enquiries, contact The Capital Network at julia@thecapitalnetwork.com.au

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.